Roka Bioscience, Inc. Announces Extended On Board Stability For All Assays On The Atlas System
WARREN, N.J., May 11, 2016 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, announced today that the Extended On Board Stability feature is now available for the Atlas System.
The new Extended on Board stability feature marks a significant advance in the flexibility, efficiency, and economics of operating the Atlas System and is designed to deliver the benefits of automation and high quality molecular technology to mid and lower volume food testing laboratories. The stability of the Atlas kits have improved from 4 days to 14 days, negating the prerequisite of high daily sample volumes in order to achieve maximum economic and workflow efficiency and furthering the Atlas System as pathogen testing solution for today's laboratories.
"Roka Bioscience is committed to continuously bringing practical, impactful testing solutions to the Food Industry. By partnering with our customers & the industry, we are able to quickly deliver new products and product advancements to our customers. This Extended On Board feature is designed to deliver the benefit of automation, traceability, and technology to a wider market and continue to elevate food testing programs across the industry," stated Mary Duseau Chief Commercial Officer at Roka Bioscience.
With a simplified workflow, that involves less hands on time, and an even faster time to result, this improvement is expected to further the Atlas System as the complete pathogen testing solution for today's food testing laboratories. For more information download the Extended On Board Stability with the Atlas System fact sheet today.
About Roka Bioscience
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit http://rokabio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the "Exchange Act"). These forward-looking statements are based on current expectations, estimates, forecasts and projections about our products and the industry and markets in which we operate and management's current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we "believe", "expect", "anticipate", "plan" and similar expressions) that are not statements of historical fact should be considered forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
For Investor or Media Related Inquires Please Contact:
Roka Bioscience, Inc.
ir@rokabio.com
855-ROKABIO (855-765-2246)
Logo - http://photos.prnewswire.com/prnh/20150714/236470LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roka-bioscience-announces-extended-on-board-stability-for-all-assays-on-the-atlas-system-300265950.html
SOURCE Roka Bioscience, Inc.
